NasdaqCM - Nasdaq Real Time Price USD

Eyenovia, Inc. (EYEN)

1.6700
+0.5400
+(47.79%)
At close: 4:00:01 PM EDT
1.7000
+0.03
+(1.80%)
After hours: 5:20:22 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
67.0630
57.3360
3.7870
0
14,000
Cost of Revenue
3,724.2490
3,927.2280
16.0050
0
1,600
Gross Profit
-3,657.1860
-3,869.8920
-12.2180
0
12,400
Operating Expense
26,637.0110
33,660.4360
25,394.2280
26,911.5150
25,420.5260
Operating Income
-30,294.1970
-37,530.3280
-25,406.4460
-26,911.5150
-13,020.5260
Net Non Operating Interest Income Expense
-2,218.8380
-2,230.4070
-1,678.2390
-1,296.7320
-385.2400
Other Income Expense
-9,866.8300
-10,057.6980
-176.4110
197.0900
627.3800
Pretax Income
-42,379.8650
-49,818.4330
-27,261.0960
-28,011.1570
-12,778.3870
Net Income Common Stockholders
-42,379.8650
-49,818.4330
-27,261.0960
-28,011.1570
-12,778.3870
Diluted NI Available to Com Stockholders
-42,379.8650
-49,818.4330
-27,261.0960
-28,011.1570
-12,778.3870
Basic EPS
-42.65
-59.81
-53.15
-66.40
-39.20
Diluted EPS
-42.65
-59.81
-53.15
-66.40
-39.20
Basic Average Shares
1,234.5860
832.9970
512.9120
420.6210
329.0510
Diluted Average Shares
1,234.5860
832.9970
512.9120
420.6210
329.0510
Total Operating Income as Reported
-41,502.0940
-48,738.2250
-25,406.4460
-26,911.5150
-13,020.5270
Total Expenses
30,361.2600
37,587.6640
25,410.2330
26,911.5150
27,020.5260
Net Income from Continuing & Discontinued Operation
-42,379.8650
-49,818.4330
-27,261.0960
-28,011.1570
-12,778.3870
Normalized Income
-32,502.3910
-39,851.3360
-27,261.0960
-28,011.1570
-13,241.7400
Interest Income
168.4340
254.0240
693.6120
83.3260
2.5160
Interest Expense
2,387.2720
2,484.4310
2,371.8510
1,380.0580
387.7560
Net Interest Income
-2,218.8380
-2,230.4070
-1,678.2390
-1,296.7320
-385.2400
EBIT
-39,992.5930
-47,334.0020
-24,889.2450
-26,631.0990
-12,390.6310
EBITDA
-39,111.8720
-46,205.5530
-24,106.0370
-26,323.6690
-12,169.0680
Reconciled Cost of Revenue
3,724.2490
3,927.2280
16.0050
0
1,600
Reconciled Depreciation
880.7210
1,128.4490
783.2080
307.4300
221.5630
Net Income from Continuing Operation Net Minority Interest
-42,379.8650
-49,818.4330
-27,261.0960
-28,011.1570
-12,778.3870
Total Unusual Items Excluding Goodwill
-9,877.4740
-9,967.0970
0
0
463.3530
Total Unusual Items
-9,877.4740
-9,967.0970
0
0
463.3530
Normalized EBITDA
-29,234.3980
-36,238.4560
-24,106.0370
-26,323.6690
-12,632.4210
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 1/25/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ARMP Armata Pharmaceuticals, Inc.
2.2500
-5.06%
 
ABP Abpro Corporation
0.2549
-6.29%
 
QNRX Quoin Pharmaceuticals, Ltd.
8.47
+6.01%
 
ENVB Enveric Biosciences, Inc.
1.3500
-0.74%
 
XLO Xilio Therapeutics, Inc.
0.8982
+2.07%
 
KLTO Klotho Neurosciences, Inc.
0.2175
-5.84%
 
PBM Psyence Biomedical Ltd.
5.32
-11.48%
 
ONCO Onconetix, Inc.
0.0880
+8.37%
 
TNFA TNF Pharmaceuticals, Inc.
0.1791
-10.14%
 
BCLI Brainstorm Cell Therapeutics Inc.
1.2400
-8.82%